The CMS has assigned a specific and permanent reimbursement J-code for Yutiq, EyePoint Pharmaceuticals announced in a press release.
Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg), a 3-year micro-insert for chronic, noninfectious uveitis, will have the code J7314, effective Oct. 1.
“The October 1st effective date of a permanent J-code specific to Yutiq will allow treating physicians, insurers and patients to benefit sooner from a more streamlined approval and reimbursement process,” Nancy Lurker, president and CEO of EyePoint, said in the release. “This key market
Uncategorized